Articles tagged with Immune Disorders
Scientists at Washington State University have discovered a novel theory that the innate immune system can respond differently to specific pathogens. This quality, known as immunological specificity, is driven by the nervous system and could provide a basis for finetuning an experimental treatment to fight infection.
Researchers have developed a method to assess drug potential for rare disorders by profiling FDA-approved drugs. The study identified NMD modulators that could potentially treat hundreds of disorders associated with nonsense-mediated RNA decay.
A large-scale review of anti-inflammatory drugs used for autoimmune disorders suggests that current treatments can worsen lipid metabolism, leading to increased cardiovascular disease risk. Researchers propose the development of combination therapies targeting lipid metabolism to reduce immune complications and CVD risk in patients.
The Sanford Children's Genomic Medicine Consortium has initiated a whole genome sequencing research project to investigate undiagnosed illnesses in children with suspected inborn errors of immunity. The study aims to sequence the genomes of up to 25 patient genomes and learn information that can benefit patients and others.
A study published in Allergy reveals the importance of PU.1 transcription factor in regulating CCL17 gene expression, which contributes to allergic diseases. The research found that suppressing PU.1 can reduce inflammation in asthmatic mice, paving the way for novel treatments.
A new study suggests that Black children are more likely to be affected by a rare immune disease that causes scar tissue to form on skin and internal organs. The research found that one in five cases of the disease involve children under 16 years old, with over 90% of these being Black.
A study of HIV-positive black and Latino men found that methamphetamine use combined with intimate partner violence boosts inflammatory and antiviral genes, leading to immune system exhaustion. This combination may increase the risk of developing cardiovascular disease and other disorders.
The German Research Foundation has approved a new Collaborative Research Center (CRC) focused on developing sustainable iron alternatives to replace toxic or rare elements. The CRC will investigate iron's potential as a building block for the future, aiming to enhance its properties and make it more affordable and resource-efficient.
A study by Tokyo University of Science researchers identifies a novel regulatory axis targeting dendritic cell activity, suppressing autoimmune disease symptoms and bone loss. They discovered DCIR binds to glycoproteins on macrophages and osteoclasts, reducing inflammation and immune responses.
A new UCL-led study found that people who survived childhood cancer have a higher risk of cardiovascular disease, infections, and disorders of the immune system by age 45. The study also suggests that cancer survivors treated with chemotherapy and radiotherapy face greater long-term health effects.
Scientists have reversed new-onset type 1 diabetes in mice by injecting pyramid-like DNA molecules called tFNAs, which increased regulatory T cells and protected pancreatic β-cells. The treatment is one of the most promising candidates for type 1 diabetes immunotherapy.
Researchers report that 90% of patients who received gene therapy between 2009 and 2012 remain disease-free, with significant immune system differences observed among those treated. The therapy is most effective in younger children, but further work is needed to achieve high levels of gene correction in all patients.
Research at Florida Atlantic University found that green sea turtles in polluted environments have impaired immune systems, leading to increased disease susceptibility. The study suggests a positive feedback loop where pollution compromises immunity, making turtles more prone to Green Turtle Fibropapillomatosis.
Researchers at UToledo have developed a protein-based vaccine that promotes a strong immune response, effectively treating rheumatoid arthritis and improving bone quality. The findings suggest long-term benefits following immunization.
A team of researchers from FAU has investigated the timing of treatment in autoimmune diseases and found that early intervention can have a major impact on disease progression. By targeting B cells, which produce autoantibodies and influence other immune cells, researchers were able to prevent or delay severe organ damage.
The FDA has granted orphan drug status to Octagam 10%, the first and only IVIg treatment for adult dermatomyositis. The therapy is expected to become the first treatment option for adults with this rare disease, which affects approximately 10 out of every million U.S. residents.
A new study examining the association between type 2 diabetes mellitus and skin diseases reveals a strong link between the two conditions. The research, published in Chinese Medical Journal, found that 93.5% of individuals with T2DM had skin problems, including over 47 types of comorbid skin diseases.
A new biomarker, HBcrAg, has been found to accurately predict viral load in patients with chronic hepatitis B and reflect response to anti-viral treatments. This discovery may lead to improved monitoring methods for CHB, enabling clinical decisions and potentially improving patient outcomes.
Researchers identified a rare case where COVID-19 triggered a recurrence of Guillain-Barré Syndrome in a 54-year-old man with prior episodes, highlighting the need for closer observation in patients with autoimmune disorders. The study provides new insights into treating COVID-19 patients with nerve-targeting autoimmune disorders.
Researchers found that elkhorn coral has a consistent immune response to diseases, indicating it actively fights off disease. The study suggests corals may have tougher epithelia and symbiotic dinoflagellates that develop differences in gene expression over time.
Research by University of Bergen scientists has found that patients with critical COVID-19 often have antibodies blocking interferons, a crucial part of the body's defense system. This finding may explain gender differences in severe COVID-19 cases and offer potential treatment options.
Researchers at UTA found a strong immune response in diseased corals leads to lower expression of genes associated with growth and reproduction. This trade-off may impact coral resilience and ecosystem recovery under climate change pressure.
A team of researchers from the University of Toronto has developed a portable, reconfigurable lab-on-a-chip diagnostic platform that can gauge immunity to vaccine-preventable diseases among vulnerable populations. The platform was validated at a refugee camp in Kenya and showed promising results in detecting measles and rubella.
Severe combined immunodeficiency disease (SCID) is a rare, deadly condition that can be cured with early diagnosis and treatment. A new review provides guidance for pediatricians and doctors on identifying and treating SCID, aiming to save lives and prevent suffering.
Researchers developed a new technique to study the gene shuffling process that creates diverse immune cell receptors. By analyzing the frequency of use of different V segment genes, they uncovered complex regulatory mechanisms involved in receptor diversity.
Researchers discovered a new class of common variable immunodeficiency disorder (CVID) caused by IKAROS gene mutations, enabling definitive genetic diagnosis and potential personalized treatment. The study found six unrelated families sharing similar symptoms and changes in the same gene, highlighting the need for early intervention.
A new type of vaccine is being developed that can trick the body into developing immunity against polio, with no risk of causing or spreading the disease. The replica virus particle will be designed to look and behave like the real virus but contain no genetic material.
Researchers have discovered a new genetic cause of familial hemophagocytic lymphohistiocytosis (FHL) type 5, a fatal immune disorder. The condition is caused by mutations in the Munc18-2 gene, leading to impaired release of death-inducing molecules from immune cells.
Researchers found a significant decline in Guillain-Barré syndrome (GBS) reports following influenza vaccination, with annual rates decreasing by 4-fold between 1993-1994 and 2002-2003. A GBS diagnosis was confirmed in 82% of reports, and preceding illness within 4 weeks of vaccination was identified in 24% of cases.
Researchers found that patients with moderate to severe Crohn's disease improved significantly after receiving GM-CSF, with 12 out of 15 patients in clinical remission. The treatment targets the innate immune response and has shown promise as an alternative approach to traditional therapies.